160
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Characterizaation of a Mycoplasma agalactiae Strain, Candidate to an Attenuated Vaccine

, , , &
Pages 1-5 | Received 24 Jun 2004, Accepted 01 Jul 2004, Published online: 11 Nov 2011
 

Abstract

Assunção, P., Fe, C. de la, Ramírez, A.S., Sarradell, J.E. and Poveda, J.B. 2004. Characterization of a Mycoplasma agalactiae strain, candidate to an attenuated vaccine. J. Appl. Anim. Res., 26: 1–5.

The aim of this work was to study the stability of a M. agalactiae attenuated strain after lyophilization and its characterization by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. Immunoblot against homologous antisera showed that the attenuated M. agalactiae strain had 2 characteristic antigenic bands of 32 and 21 kDa. The assays related to strain lyophilization showed that the CFUs were decreased lesser than 2log10 after 1 year storage at 4C with the exception of one vial, which lost all its viability. The subcutaneous inoculation dose (105 CFU), did not produce any symptom or sign of disease during the 45 days of the experiment. However, a local reaction was observed on the day after the inoculation. At necropsy, no macroscopic lesions were found which related to contagious agalactia or other disease. These results suggest that this attenuated strain has good possibilities as a live attenuated vaccine.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.